Cost-effectiveness of the National Health Service abdominal aortic aneurysm screening programme in England by Glover, MJ et al.
Original article
Cost-effectiveness of the National Health Service abdominal
aortic aneurysm screening programme in England
M. J. Glover1, L. G. Kim2, M. J. Sweeting3, S. G. Thompson3 and M. J. Buxton1
1Health Economics Research Group, Brunel University, and 2Department of Medical Statistics, Faculty of Epidemiology and Population Health, London
School of Hygiene and Tropical Medicine, London, and 3Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
Correspondence to: Mr M. J. Glover, Health Economics Research Group, Brunel University, Uxbridge UB8 3PH, UK (e-mail:
Matthew.Glover@brunel.ac.uk)
Background: Implementation of the National Health Service abdominal aortic aneurysm (AAA)
screening programme (NAAASP) for men aged 65 years began in England in 2009. An important
element of the evidence base supporting its introduction was the economic modelling of the long-term
cost-effectiveness of screening, which was based mainly on 4-year follow-up data from the Multicentre
Aneurysm Screening Study (MASS) randomized trial. Concern has been expressed about whether this
conclusion of cost-effectiveness still holds, given the early performance parameters, particularly the
lower prevalence of AAA observed in NAAASP.
Methods: The existing published model was adjusted and updated to reflect the current best evidence.
It was recalibrated to mirror the 10-year follow-up data from MASS; the main cost parameters were
re-estimated to reflect current practice; andmore robust estimates of AAA growth and rupture rates from
recent meta-analyses were incorporated, as were key parameters as observed in NAAASP (attendance
rates, AAA prevalence and size distributions).
Results: The revised and updated model produced estimates of the long-term incremental cost-
effectiveness of £5758 (95 per cent confidence interval £4285 to £7410) per life-year gained, or £7370
(£5467 to £9443) per quality-adjusted life-year (QALY) gained.
Conclusion: Although the updated parameters, particularly the increased costs and lower AAA
prevalence, have increased the cost per QALY, the latest modelling provides evidence that AAA
screening as now being implemented in England is still highly cost-effective.
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Introduction
The UK Multicentre Aneurysm Screening Study (MASS)
investigated the effects of offering population screening
for abdominal aortic aneurysm (AAA) to men aged
65–74 years. The results of this randomized trial1, first
reported at 4 years of follow-up in 2002, demonstrated that
invitation to a one-time ultrasound screen and follow-up of
identified aneurysms was effective in reducing AAA-related
mortality. This clinical finding has been confirmed by
longer-term follow-up from MASS2–4, and reinforced by
systematic reviews5,6 of evidence including other relevant
trials. Based on the initial MASS results it was evident
that screening in the context of the UK was likely to
be cost-effective in the long-term7. This expectation was
confirmed by a formal model that extrapolated from the 4-
year follow-up data to estimate the long-term incremental
cost per quality-adjusted life-year (QALY) for a screening
programme of 65-year-old men, using the same screening
methods and rescanning intervals for detected aneurysms
as in MASS8. This estimated the incremental cost per
QALY gained for those invited to screening compared
with those not invited as £2970 (95 per cent uncertainty
interval £2030 to £5430).
In the light of this clinical and cost-effectiveness evi-
dence, and a positive review of all its criteria for a
new screening programme, the UK National Screening
Committee recommended that a National Health Service
(NHS) AAA screening programme (NAAASP) be intro-
duced. Phased implementation began in March 2009 with
the aim to cover the whole of England by March 20139,10.
Implementation is also under way in Wales, Scotland and
Northern Ireland.
 2014 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.
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Early information from the NAAASP is now available,
and it has been noted particularly that the prevalence of
AAA at screening is considerably lower than that found
in MASS (1·5 per cent compared with 4·9 per cent for
MASS)1,10. This paper re-estimates the cost-effectiveness
of AAA screening as operationalized in England using the
most up-to-date available data. The changes to the model
reflect: a recalibration to take account of the 10-year follow-
up of MASS, using individual patient data; incorporation
of updated cost parameters reflecting the current costs of
screening, rescans and procedures, including allowance for
the introduction of elective endovascular aneurysm repair
(EVAR); the use of more robust estimates of AAA growth
and rupture rates based on recent meta-analyses11,12 of
individual patient data; and key parameters observed in
NAAASP to date (attendance rates, AAA prevalence and
aortic size distribution).
Methods
Original model
This re-estimation of the long-term cost-effectiveness
of offering AAA screening used the cost-effectiveness
model reported in 20078. The underlying Markov model
structure is shown in Fig. 1 and remained unchanged in
this reanalysis. The two populations (those invited to AAA
screening and those not invited) are modelled using 3-
month cycles; each arrow in Fig. 1 represents a possible
transition. The original model incorporated information
from a range of sources to chart the detection, growth
and treatment of AAAs over time for these populations,
using the 4-year follow-up data from MASS as its prime
source. It allowed estimation of 30-year costs and benefits
of a programme offering a one-off screen to men aged
65 years with repeat scanning annually for aneurysms with
a diameter of 3·0–4·4 cm (small AAA) and every 3months
for those with a diameter of 4·5–5·4 cm (medium AAA).
Men with aneurysms over 5·4 cm (large AAA) would be
referred for consideration for elective surgery. The model
adopted an NHS perspective of costs.
Revalidation and recalibration
The original model had been validated against the 4-
year MASS data and shown to perform satisfactorily13.
Using the longer 10-year follow-up data reported for
MASS3, a revalidation exercise was undertaken to assess
how well the model predicted the longer-term observed
data and to inform recalibration where necessary. Numbers
of key events and cost-effectiveness (at 2008–2009 prices)
Non-AAA
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Opportunistic
detection
Drop-out from
follow-up
Small AAA Small AAA
Medium
AAA
Medium
AAA
Large AAA Large AAA
No AAA
Screen invite
No screen invite
Contra-
indicated Consultation
Rupture
Emergency
operation
Elective operation
AAA death Survived
surgery
Undetected Detected
Elective
operation
pending
Fig. 1 Markov model structure. AAA, abdominal aortic aneurysm.
Reproduced from Kim et al.8, with permission from Journal of
Medical Screening
observed in the trial were compared with results from the
model.
To account for any emerging time trends in observed
parameters, regression methods were used to derive time-
dependent transition probabilities. Based on MASS, 10-
year data probabilities were estimated for each 3-monthly
cycle, determining transitions between states in the model.
Recalibrations of parameter estimates for the rate of
opportunistic detection and the rupture rate in large
undetected AAAs were also carried out. These parameters
cannot be estimated directly from MASS data; hence
estimates were chosen to fit the observed data, with a
focus on calibration to reflect best the incremental cost-
effectiveness ratio (ICER) at 10 years based on observed
follow-up. Rates were adjusted to minimize disparity in
 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 976–982
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Table 1 Unit costs: original estimates from the Multicentre Aneurysm Screening Study, costs inflated to 2010–2011 prices,
re-estimated unit costs, cost distributions applied in probabilistic sensitivity analysis, and source
Cost component
Original cost
2000–2001 (£)
MASS cost
inflated to 2010–2011 (£)
Re-estimated
unit cost (£) Distribution* Source
Invitation to screen 1·31 1·84 1·70 Normal(1·7, 0·17)† NAAASP
Cost of first scan 19·08 26·80 32·20 Normal(32·2, 3·22)† NAAASP
Surveillance scan 46·04 64·67 68·00 Normal(68·0, 6·80)† NAAASP
Presurgical assessment 309·88 435·25 435·25 Normal(435·25, 87·05)‡ MASS
Elective repair 6909·00 9704·24 12 806·21 Normal(12 806, 2561)‡ Thompson et al.14
Emergency repair 11 176·00 15 697·59 19 984·75 Normal(19 985, 3996)‡ Thompson et al.14
*Normal(µ, σ); standard deviation (σ) †10 per cent and ‡20 per cent of point estimate. MASS, Multicentre Aneurysm Screening Study; NAAASP,
National Health Service abdominal aortic aneurysm screening programme.
the modelled and observed differences between arms
in key events. A previously published Health Technology
Assessment monograph14 deals with this process more
comprehensively.
Re-estimation of unit costs
Following the model calibration, input parameters were
updated to reflect contemporary costs. The unit cost
estimates used in the original modelling related to the
costs of screening as undertaken in MASS, and to
contemporaneous estimates of the costs of elective and
emergency procedures7. They were originally estimated at
2000–2001 prices, and in subsequent analyses were simply
uplifted to account for general health service inflation. In
this updated analysis, costs have been re-estimated and
are presented at 2010–2011 price levels. Unit cost data
for the screening itself were obtained from NAAASP14.
Data from MASS7, the EVAR-1 trial15 and the National
Vascular Database16 were used to re-estimate the cost of
surgical procedures. Table 1 shows the original aneurysm
repair costs, together with the updated unit costs. A
fuller account of this re-estimation has been published
elsewhere14.
Clinical data
The majority of probabilistic parameters that determine
transitions between states in the Markov model have been
updated using the 10-year follow-up data from MASS3
(Table 2). The postcalibration model was also updated to
reflect available data from the current NAAASP. Data for
attendance rates at screening (75 per cent versus 80 per
cent in MASS), AAA prevalence (1·5 per cent versus 4·9
per cent in MASS) and the size distribution of aneurysms
at initial screening (similar in NAAASP and MASS)10
were incorporated (Table 2). Sensitivity analysis around the
30-day surgical mortality rate was also conducted. The
mortality rate after elective intervention for a screen-
detected AAA observed in the NAAASP was lower (1·6
per cent versus 3·0 per cent in MASS), but based on few
deaths, so it was deemed inappropriate to use it in the base
case. Given the trend of an observed fall in the prevalence
rate, a threshold analysis was also conducted to estimate
the rate at which the modelling suggests the ICER would
rise above £20 000 per QALY.
Growth and rupture rate estimates
The postcalibration model also included improved
estimates of aneurysm growth and rupture rates which
were derived from the meta-analyses of individual patient
data from 18 longitudinal studies of AAA screening
surveillance programmes, undertaken as part of the
RESCAN Collaboration11. The statistical methods used
in these meta-analyses have been described elsewhere11,19,
as has their incorporation into the modelling14.
Implementation of the model
As before, the model was implemented in Microsoft
Excel (Microsoft, San Diego, California, USA), and a
30-year time horizon was adopted (essentially constituting
a lifetime for the 65-year-old men considered). Long-term
cost and life-years accrued in populations invited to, and
not invited to, screening are the outcomes of interest, both
discounted at 3·5 per cent per annum. As in previous ver-
sions of the modelling, QALYs are estimated by adjusting
life-year estimates by EQ-5D (EuroQol Group, Rot-
terdam, The Netherlands) utility values for UK-relevant
population age norms20. No further adjustment was made,
based on the lack of differences in quality of life of those
with an AAA1. Age-specific death rates from causes other
than AAA were taken from UK national statistics18.
The results are presented as an ICER of invitation to
the screening programme compared with no invitation to
screening. Probabilistic sensitivity analysis was undertaken
 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 976–982
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Table 2 Clinical parameters: point estimate used in the model, distribution applied in probabilistic sensitivity analysis, and source
ecruoS*noitubirtsiDetamitsE
0gnineercsotdetivniernoitroporP · SSAM)73292,2064(ateB0631
Prevalence of AAA at first screen
0srednettA ·0151 Beta(1619, 105 432) NAAASP
0srednetta-noN ·0151 Beta(1619, 105 432) NAAASP
0AAAdezilausiv-noN ·0151 Beta(1619, 105 432) NAAASP
0dezilausiv-nonsnacsfonoitroporP · SSAM)81862,923(ateB1210
0gnidnettadetivni-neercsfonoitroporP ·750 Beta(93 170, 31 022) NAAASP
0neercstsrfitasAAAllamsfonoitroporP · PSAAAN987
0neercstsrfitasAAAmuidemfonoitroporP ·119 Dirichlet(1278, 193, 148) NAAASP
0neercstsrfitasAAAegralfonoitroporP · PSAAAN190
Transition probabilities (3-monthly)
0AAAllamsotAAAonmorfworG ·00207 Gamma(27, 7·66 × 10−5) Scott et al.17
PTDTAAAmuidemotllamsmorfworG ‡ RESCAN
Multiplier ∼ Normal(1, 0·1)
PTDTAAAegralotmuidemmorfworG § RESCAN
0ecnallievrusmorftuo-pordfoytilibaborP ·0142 Gamma(330, 4·34 × 10−5) MASS
Rupture
noitpmussA.a.n0AAAoN
PTDTAAAllamS ¶ RESCAN
Multiplier ∼ Normal(1, 0·35)
NACSER#PTDTAAAmuideM
0AAAegraldetceteD ·0125 Gamma(23, 0·00055) MASS
Undetected large AAA† 0· detarbilaC.a.n2820
0yregrusrofdetacidniartnoC ·0282 Gamma(19, 0·0015) MASS
0noitcetedcitsinutroppO · detarbilaC.a.n4110
0erutpurretfayregrusycnegremE · SSAM)133,391(ateB863
0yregrusycnegremeretfahtaeD · SSAM)721,66(ateB243
0yregrusgnivahsAAAegralfonoitroporP · SSAM186
0gnineercsotdenrutersAAAegralfonoitroporP ·221 Dirichlet(481, 156, 69) MASS
Proportion of large AAAs contraindicated for elective surgery 0· SSAM7790
Death after elective surgery
0AAAdetceted-neercS · SSAM)305,51(ateB8920
0AAAdetcetedyllacitsinutroppO · SSAM)152,81(ateB7170
All-cause mortality
0yregrusrofdetacidniartnoC ·0599 Gamma(41, 0·0015) MASS
scitsitatSlanoitaNrofecfifO.a.ncfiiceps-egAcfiiceps-egA 18
*Beta(α, β); Gamma(α, β); Dirichlet(α1 . . . αk); Normal(µ, σ). †Cannot be observed directly; value chosen during recalibration exercise. ‡Mean 0·016;
§mean 0·077; ¶mean 0·00076; #mean 0·0064. MASS, Multicentre Aneurysm Screening Study; AAA, abdominal aortic aneurysm; NAAASP, National
Health Service abdominal aortic aneurysm screening programme; TDTP, time-dependent transition probability; RESCAN, RESCAN Collaboration;
n.a., not available.
to allow for parameter uncertainty, providing 1000
simulated ICER values. The distributions used for the
uncertainty around the point estimate of each variable are
detailed in Tables 1 and 2. For the updated time-dependent
growth and rupture rates, a normally distributed multiplier
(with mean 1 and based on a conservative approximation
of the standard deviation from the mean of the pooled
rates) was defined and sampled from, in order to increase
or decrease all growth or rupture rates over time by a
constant factor.
Results
The revalidation process showed that the original model
did not perform particularly well in predicting the observed
MASS 10-year data. There were a number of discrepancies
that together led to a substantial difference in the estimate
of the 10-year ICER (Table 3). Recalibration attempted
to minimize the discrepancy in the estimated ICER. The
recalibrated model predicted a 10-year ICER of £8900,
compared with an ICER based on the 10-year observed
data of £7600 per life-year.
The updated 2010–2011 costs for screening and rescans
were considerably higher than the 2000–2001 figures
originally derived from MASS (Table 1). Although this
increase reflects general health service inflation, most
of these specific costs have increased more rapidly. For
example, the cost of elective repair now reflects the
proportion of cases in which EVAR is used, leading to
a cost that was 32 per cent higher than the inflated value
 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 976–982
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Table 3 Abdominal aortic aneurysm screening model: validation
and recalibration of results using original cost estimates inflated
to 2008–2009 prices for consistency
Observed in
MASS*
Original
model†
Model after
recalibration to
MASS 10-year
follow-up data‡
Control group
Elective operations 226 256 213
Emergency operations 141 140 168
AAA deaths 296 305 385
Non-AAA deaths 10 185 10 139 10 148
Life-years (mean) 7·509 7·291 7·282
Mean cost (£) 108 118 124
Invited group
Elective operations 552 607 539
Emergency operations 62 88 97
AAA deaths 155 202 248
Non-AAA deaths 10 119 10 185 10 189
Mean life-years 7·523 7·297 7·293
Mean cost (£) 208 233 225
Difference between arms
Elective operations 326 351 326
Emergency operations −79 −52 −71
AAA deaths −141 −103 −137
Non-AAA deaths −66 46 41
Mean difference in life-years 0·013 0·006 0·011
Mean difference in cost (£) 100 115 101
ICER (£)
Life-years 7600 18 000 8900
QALYs 9700 23 000 11 400
*Key events and cost-effectiveness observed in Multicentre Aneurysm
Screening Study (MASS) at 10-year follow-up. †Key events and
cost-effectiveness results of modelling, using time-constant parameter
estimates from MASS 10-year follow-up. ‡Key events and
cost-effectiveness results of modelling, with time-dependent parameter
estimates from MASS 10-year follow-up and after recalibration exercise.
AAA, abdominal aortic aneurysm; ICER, incremental cost-effectiveness
ratio; QALY, quality-adjusted life-year (adjusted using population norms).
of the original estimate. The estimate for an emergency
repair was also 27 per cent higher.
The new estimates of life-years, costs and cost-
effectiveness results, over a 30-year time horizon, for an
AAA screening programme are shown in Table 4. The
ICER is now £5758 (95 per cent confidence interval £4285
to £7410) per life-year gained and £7370 (£5467 to £9443)
per QALY gained.
When presented on the cost-effectiveness plane (Fig. 2),
the 1000 iterations of the probabilistic sensitivity analysis
show that, in all cases, the intervention provides additional
QALYs but costs more. The figure demonstrates the low
level of remaining uncertainty and that all estimates fall
below the £20 000 threshold, as used by the National
Institute for Health and Care Excellence (NICE)21.
Furthermore, for any threshold value of a QALY over
Table 4 Abdominal aortic aneurysm screening model: 30-year
cost-effectiveness results at 2010–2011 prices for the current
National Health Service abdominal aortic aneurysm screening
programme
Control group Invited group Difference
Life-years† 12·719 12·727 0·0084
QALYs† 9·921 9·928 0·0067
Costs (£) 269 316 47
ICER (£)‡
Life-years 5758 (4285, 7410)
QALYs 7370 (5467, 9443)
Values in parentheses are 95 per cent confidence intervals. Modelling
after recalibration, incorporating Multicentre Aneurysm Screening Study
(MASS) 10-year follow-up data, growth and rupture rates from
meta-analysis of patient-level data, National Health Service abdominal
aortic aneurysm screening programme (NAAASP) data on attendance,
prevalence and abdominal aortic aneurysm size at initial screen and
updated costs. †Life-years and costs discounted at 3·5 per cent.
‡Estimated from the mean of incremental cost-effectiveness ratios
(ICERs) produced by 1000 probabilistic sensitivity analysis iterations.
QALY, quality-adjusted life-year.
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Fig. 2 National Health Service abdominal aortic aneurysm
screening programme (NAAASP) cost-effectiveness estimates
(30 years); 1000 probabilistic sensitivity analysis iterations.
QALY, quality-adjusted life-year
£10 000, there is at least a 99 per cent probability that the
programme is cost-effective.
The probabilistic sensitivity analysis incorporated the
uncertainty around the postsurgical mortality observed
in MASS; a one-way sensitivity analysis using the lower
mortality rate observed in NAAASP, based on limited
data, reduced the latter ICER by approximately £300. One-
way sensitivity analysis suggests that the cost-effectiveness
ratio would rise above the NICE £20 000 threshold at a
prevalence of AAA in 65-year-old men of 0·35 per cent,
compared with the observed 1·5 per cent.
 2014 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2014; 101: 976–982
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Discussion
To assess the cost-effectiveness of many interventions,
particularly screening where the bulk of costs are upfront,
but benefits are accrued over time, long-term modelling is
essential. It is rare to be able to revisit a model originally
constructed using short-term (4-year) trial evidence and
compare modelled results with more robust mid-term
(10-year) trial data. Such models may not, however, as
here, predict well over the medium term. The efforts to
recalibrate the model confirmed that the cost-effectiveness
estimates are more sensitive to the modelled differences
between arms in costs and outcomes (incremental costs
and QALYs) than the absolute values in each arm.
For that reason, the focus of calibration should be on
these differences that drive the cost-effectiveness ratio.
The revalidation exercise undertaken demonstrates that
economists should be cautious in the use of models based
on relatively short-term data13, given that they may not
extrapolate well to medium- or long-term outcomes.
These new analyses have not simply been updated to
reflect longer-term trial data. Data from recent meta-
analyses of aneurysm rupture and growth rates were used
to estimate the growth and rupture rates over the long term.
New unit cost estimates for the screening procedure and
for AAA surgery that reflect current practice in the UK
were incorporated. The new cost estimates demonstrate
that, although simple adjustment using relevant price
indices may be adequate for some unit costs, for some
the procedure costs need to be re-estimated to reflect
changes in the costs of particular resources, and changes in
the process of care.
Most importantly from a policy perspective, the
model incorporates key parameters from the first years
of NAAASP: attendance, AAA prevalence and size
distribution at first screen. The combined changes do
mean that the estimated 30-year ICER of £7370 per QALY
gained has increased; the originalmodel estimated an ICER
of £2970 per QALY gained8. The increase in the estimated
ICER reflects the incorporation into the modelling of the
much lower AAA prevalence found by NAAASP (1·5 per
cent) compared with MASS (4·9 per cent). It also reflects,
as might be expected, the fact that the cost of screening
has increased since the first costing exercise was conducted
in 2001. The costs of elective and emergency AAA repair
have increased well above general health service inflation,
in part due to the use of more expensive EVAR procedures.
Despite the increase in the estimated ICER, the
new modelling demonstrates with confidence that AAA
screening remains highly cost-effective, with an ICER
well below the lower limit of NICE’s acceptable cost-
effectiveness range of £20 000–30 000 per QALY gained.
The probabilistic sensitivity analysis suggests that, even at a
level of £10 000 perQALY, the probability thatNAAASP is
cost-effective is 99 per cent, thus providing strong support
for cost-effectiveness of the current screening programme
in the UK.
Although early estimates of the cost-effectiveness of
AAA screening predating the publication of results
from randomized trials were very variable22, and precise
estimates of cost-effectiveness are necessarily country-
specific, there is now a growing international consensus
that one-off ultrasound screening in men at around age
65 years is cost-effective. This conclusion for the UK is
paralleled by studies relating to Canada23, Denmark24,25,
The Netherlands26, Norway26, Northern Ireland27 and
Italy28, with only one recent contrary estimate, also from
Denmark29.
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